Telitacicept（Cat No.:I042120）is a monoclonal antibody designed to inhibit the activity of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), both of which are involved in the development of autoimmune diseases. By targeting these molecules, Telitacicept aims to reduce B-cell activity, which plays a key role in autoimmune conditions such as systemic lupus erythematosus (SLE). Clinical trials have shown promise in reducing disease activity and symptoms in patients with autoimmune disorders. Ongoing studies continue to evaluate its safety, efficacy, and long-term effects in various conditions.
